Print

Featured Studies Results

Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)

https://www.facingourrisk.org/research-clinical-trials/study/372/using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle

Clinicaltrials.gov identifier:
NCT05059444 (https://clinicaltrials.gov/show/NCT05059444)

Treatment
Post-treatment study to monitor for recurrence

ADHERE: Survey about Pancreatic Cancer Screening Options for People with Inherited Risk

https://www.facingourrisk.org/research-clinical-trials/study/368/adhere-survey-about-pancreatic-cancer-screening-options-for-people-with-inherited-risk

Surveys, Registries, Interviews
Online survey about pancreatic cancer screening for people with an inherited mutation in genes that are linked to an increased risk of pancreatic cancer

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

https://www.facingourrisk.org/research-clinical-trials/study/356/treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies

Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)

Treatment
Treatment study for people with advanced or metastatic cancers

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/314/neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer

Clinicaltrials.gov identifier:
NCT05498272 (https://clinicaltrials.gov/show/NCT05498272)

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

Vaccine for People at High Risk for Pancreatic Cancer

https://www.facingourrisk.org/research-clinical-trials/study/365/vaccine-for-those-at-high-risk-of-developing-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT05013216 (https://clinicaltrials.gov/show/NCT05013216)

Prevention
Phase 1 pancreatic cancer prevention study for people at high risk

Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)

https://www.facingourrisk.org/research-clinical-trials/study/371/comparing-an-investigational-targeted-drug-azd5335-to-standard-treatments-in-people-with-platinumresistant-ovarian-cancer-trevioc01

Clinicaltrials.gov identifier:
NCT07218809 (https://clinicaltrials.gov/show/NCT07218809)

Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer

Research Study on the Genetics of Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/317/research-study-on-the-genetics-of-breast-cancer

Clinicaltrials.gov identifier:
NCT06773897 (https://clinicaltrials.gov/show/NCT06773897)

Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States

Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling

https://www.facingourrisk.org/research-clinical-trials/study/321/pfizer-clinical-trials-for-metastatic-prostate-cancer-are-now-enrolling

Treatment
Men aged 18 years or older with metastatic prostate cancer

Cancer Patients: Share Your Experience Talking With Surgeons About Treatment Decisions

https://www.facingourrisk.org/research-clinical-trials/study/374/cancer-patients-share-your-experience-talking-with-surgeons-about-treatment-decisions

Surveys, Registries, Interviews
Survey for adults with cancer who discussed possible surgery with a surgeon

Treating Advanced or Metastatic Breast Cancer with a Type of Immunotherapy Called CAR-T

https://www.facingourrisk.org/research-clinical-trials/study/364/treating-advanced-or-metastatic-breast-cancer-with-a-type-of-immunotherapy-called-car-t

Clinicaltrials.gov identifier:
NCT06878248 (https://clinicaltrials.gov/show/NCT06878248)

Treatment
Phase 1 treatment study for people with advanced solid tumors

Comparing an Experimental Drug Puxi-Sam to Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar‑Endometrial01)

https://www.facingourrisk.org/research-clinical-trials/study/370/comparing-an-experimental-drug-puxi-sam-with-standard-chemotherapy-for-metastatic-endometrial-cancer-bluestarendometrial01

Clinicaltrials.gov identifier:
NCT07044336 (https://clinicaltrials.gov/show/NCT07044336)

Treatment
Phase 3 treatment study for metastatic endometrial cancer

Treating Recurrent dMMR or MSI-High Endometrial Cancer with the Immunotherapy Drug, Nivolumab with or without the Immunotherapy Drug, Ipilimumab

https://www.facingourrisk.org/research-clinical-trials/study/362/testing-an-immunotherapy-drug-nivolumab-with-or-without-the-immunotherapy-drug-ipilimumab-for-recurrent-dmmr-endometrial-cancer

Clinicaltrials.gov identifier:
NCT05112601 (https://clinicaltrials.gov/show/NCT05112601)

Treatment
Phase 2 treatment study for recurrent endometrial cancer with dMMR or MSI-High biomarker

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/360/the-prostate-cancer-genetic-risk-and-equitable-screening-study-progress

Clinicaltrials.gov identifier:
NCT05926102 (https://clinicaltrials.gov/show/NCT05926102)

Prevention
Prostate cancer screening study for male US veterans age 55–69

Study of an Investigational Drug, E7386 Plus Lenvatinib in People with Endometrial Cancer after Chemotherapy and Immunotherapy

https://www.facingourrisk.org/research-clinical-trials/study/355/study-of-a-new-drug-e7386-in-combination-with-lenvatinib-in-people-with-previously-treated-endometrial-cancer

Clinicaltrials.gov identifier:
NCT04008797 (https://clinicaltrials.gov/show/NCT04008797)

Treatment
Treatment study for people with previously treated endometrial cancer

Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/353/using-biparametric-magnetic-resonance-imaging-mri-as-a-screening-tool-for-those-at-high-risk-for-prostate-cancer

Clinicaltrials.gov identifier:
NCT05384535 (https://clinicaltrials.gov/show/NCT05384535)

Prevention
Screening for people at high risk for prostate cancer

Understanding Access to Genetic Services for Latina Women with Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/367/understanding-access-to-genetic-services-for-latina-women-with-breast-cancer

Surveys, Registries, Interviews
A phone survey for Latina breast cancer survivors diagnosed within the past five years in California

Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)

https://www.facingourrisk.org/research-clinical-trials/study/363/testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors

Clinicaltrials.gov identifier:
NCT05372640 (https://clinicaltrials.gov/show/NCT05372640)

Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors

Study of a New Drug, Sacituzumab Tirumotecan, Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer (TroFuse-011)

https://www.facingourrisk.org/research-clinical-trials/study/359/study-of-a-new-drug-sacituzumab-tirumotecan-given-alone-or-in-combination-with-an-immunotherapy-for-people-with-triple-negative-breast-cancer

Clinicaltrials.gov identifier:
NCT06841354 (https://clinicaltrials.gov/show/NCT06841354)

Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.